公司資料
Endra 股價、新聞與催化劑
- 股票代碼:
- NDRA
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
5.88 USD (-1.34%)
收盤價
最後更新: 2026年10月1日
9.32M USD
市值
股價為何變動
截至 2026年10月1日，NDRA 下跌 1.34%，收於 $5.88。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Liver Imaging Technology Company
ENDRA Life Sciences develops thermoacoustic imaging technology for measuring liver fat. Its TAEUS platform is intended to provide a lower-cost, point-of-care alternative to MRI-based quantification.
TAEUS Liver System
TAEUS uses short radiofrequency pulses to stimulate tissue and ultrasound sensors to detect the resulting acoustic response. The system estimates liver fat fraction without ionizing radiation or contrast agents.
MASLD and MASH Monitoring
Quantitative liver-fat measurement can support detection and longitudinal monitoring of metabolic dysfunction-associated steatotic liver disease. ENDRA aims to place this capability in clinics that already use conventional ultrasound.
Clinical Validation Program
The company has conducted feasibility and repeatability studies comparing TAEUS measurements with MRI proton-density fat fraction. Results are being used to refine the device and design a pivotal U.S. clinical study.
De Novo Regulatory Pathway
ENDRA has engaged with the FDA on device configuration, study design, and a De Novo submission pathway. Clearance would be required before broad commercialization in the United States.
未來催化劑
- Initiation and completion of the pivotal U.S. study intended to support a De Novo submission for TAEUS Liver.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。